QIAGEN N.V. QGEN
NYSE · XNYS · stock · Biological Products, (No Diagnostic Substances)
Chart by TradingView
7/9
Piotroski F — financial health
5.06
Altman Z″ — distress risk · safe
12.8%
Dividend payout · safe
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $2.1B | $424.9M | $1.3B | $453.3M | $3.8B |
| 2024 | $2.0B | $83.6M | $967.4M | $506.4M | $3.6B |
| 2023 | $2.0B | $341.3M | $1.2B | $309.7M | $3.8B |
| 2022 | $2.1B | $423.2M | $1.4B | $586.0M | $3.5B |
| 2021 | $2.3B | $512.6M | $1.5B | $449.1M | $3.1B |
| 2020 | $1.9B | $359.2M | $1.2B | $325.0M | $2.8B |
Recent insider activity (Form 4)
| Insider | Role | Date | Action | Shares | Price |
|---|---|---|---|---|---|
| QIAGEN NV | 10% owner | 2007-06-15 | Buy | 10,000 | $1.35 |
| QIAGEN NV | 10% owner | 2007-06-12 | Buy | 10,000 | $1.29 |
| QIAGEN NV | 10% owner | 2007-06-04 | Buy | 50,000 | $1.31 |
| QIAGEN NV | 10% owner | 2007-05-31 | Buy | 5,000 | $1.31 |
| QIAGEN NV | 10% owner | 2007-05-30 | Buy | 30,000 | $1.31 |
| QIAGEN NV | 10% owner | 2007-05-29 | Buy | 10,000 | $1.31 |
| QIAGEN NV | 10% owner | 2007-05-23 | Buy | 17,500 | $1.29 |
| QIAGEN NV | 10% owner | 2007-05-09 | Option exercise | 240,000 | $0.45 |
Why these scores methodology →
Piotroski F-score: 7/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 5.06 (safe)
- Working capital / assets 0.236
- Retained earnings / assets 0.438
- EBIT / assets 0.074
- Equity / liabilities 1.509
Source: SEC EDGAR filings · CIK 0001015820 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.